Skip to main content
main-content

Chronic myeloid leukaemia

17-03-2017 | Chronic myeloid leukaemia | News | Article

Imatinib efficacy for CML sustained over time

Overall survival among patients with chronic myeloid leukemia remains high after nearly 11 years of treatment with imatinib, analysis of phase III study data shows.

Source:

N Engl J Med 2017; 376: 917–927, 982–983

06-01-2017 | Chronic myeloid leukaemia | News | Article

CD62L T-cell expression linked to TKI therapy response

Chronic myeloid leukemia patients with high CD62L T-cell expression and low soluble CD62L plasma levels at diagnosis have the best chance of achieving a deep molecular response to first-line therapy with tyrosine kinase inhibitors, study findings indicate.

Source:

J Clin Oncol 2016; Advance online publication

04-01-2017 | Chronic myeloid leukaemia | News | Article

Editor's pick

Imatinib kinetic response similar in children and adults

Primary kinetic responses to the tyrosine kinase inhibitor imatinib do not differ significantly between children and adults with chronic myeloid leukemia, German study data show.

Source:

Haematologica 2016; Advance online publication

30-12-2016 | Chronic myeloid leukaemia | News | Article

Mature NK cells play key role in continued CML remission

Patients with chronic myeloid leukemia who successfully discontinue imatinib treatment have a higher proportion of mature natural killer cells than those who experience early relapse, a substudy of the EURO-SKI data shows.

Source:

Leukemia 2016; Advance online publication

28-12-2016 | Chronic myeloid leukaemia | News | Article

Fecal occult blood test ‘useful’ for detecting dasatinib-induced hemorrhagic colitis

Japanese researchers say that a fecal occult blood test could help screen for treatment-induced hemorrhagic colitis in chronic myeloid leukemia patients taking dasatinib.

Source:

Blood 2016; Advance online publication

01-12-2016 | Chronic myeloid leukaemia | News | Article

STIM1 findings confirm safety of controlled imatinib discontinuation

Final results of the Stop Imatinib trial confirm that the tyrosine kinase inhibitor can be safely discontinued in chronic myeloid leukemia patients who achieve a sustained deep molecular response.

Source:

J Clin Oncol 2016; Advance online publication 

image credits